Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

56.23 -0.59 (-1.03%)
Streaming Delayed Price Updated: 2:50 PM EST, Jan 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
67 68 Next >
A New Depression Drug Being Developed By Tonix May Side-Step Treatment-Limiting Effects Of Nearly All Current Antidepressants In The US
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. The sponsored content team works to ensure... 
Via Benzinga
US Stocks Eye Higher Open As Meta Q1 Uplifts Tech Sector: Analyst Says 'No Earnings Recession In Cards Yet'
Tech earnings could come to the market’s rescue on Thursday, with all major index futures currently trading higher. 
Via Benzinga
Bristol Myers Squibb Reports First Quarter Financial Results for 2023
From Bristol Myers Squibb
Via Business Wire
Bristol-Myers Squibb Earnings Conference Call Is Coming Up, Here's What You Need To Know
Via Benzinga
This Is What Whales Are Betting On Bristol-Myers Squibb
Via Benzinga
Where Bristol-Myers Squibb Stands With Analysts
Via Benzinga
Bristol Myers Squibb Announces Leadership Transition Plan
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
From Bristol Myers Squibb
Via Business Wire
LianBio Touts Positive Data From Bristol Myers-Partnered Heart Drug In Chinese Patients
LianBio (NASDAQ: LIAN) announced  
Via Benzinga
This House of Representative Just Sold Up To $265K In Bristol-Myers Squibb Stock
Via Benzinga
2 Top Stocks to Buy in April and Hold Forever
The need for healthcare goods and/or services is here to stay. 
Via The Motley Fool
2 Ultra-Cheap Dividend Stocks to Buy in April
These two big pharma stocks are trading at steep discounts. 
Via The Motley Fool
Allarity Therapeutics Accelerates Trial Enrollment To Bring FDA-Approved Breast Cancer Treatment To European Market – Interim Results Could Be Released In Second Half Of 2023
Recently, Allarity Therapeutics, Inc. (NASDAQ: ALLR) announced plans to speed up its Phase 2 clinical trial for IXEMPRA®, the clini 
Via Benzinga
Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production
From Bristol Myers Squibb
Via Business Wire
This Supercharged Dividend King Stock Might Soon Run Out of Steam
Emerging competitive threats in immunology, oncology, and medical aesthetics, along with a highly leveraged balance sheet, might dampen the drugmaker's growth trajectory post-2025. 
Via The Motley Fool
Why Legend Biotech Stock Is Having Its Best Month Yet
With the biotech market’s focus back on treatments for cancer and other life-threatening diseases, Legend has now tripled off its bottom to a record high. 
Via MarketBeat
Want Consistently Growing Passive Income? Buy Johnson & Johnson Stock
The healthcare juggernaut recently extended its illustrious dividend growth streak. 
Via The Motley Fool
Second Quarter Outlook For Biotech Stocks
Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity. 
Via Talk Markets
Is Aurinia Pharmaceuticals Up for Grabs? Shareholder Suggests a Quick Sale for a Bigger Payday
Via Benzinga
The Smartest Stocks to Buy With $20 Right Now and Hold Forever
These cheap stocks have the potential to skyrocket over the long haul. 
Via The Motley Fool
Thinking Of Buying Healthpeak Properties? Here Are The Properties And Tenants You'd Be Adding To Your Portfolio
Real estate investment trusts (REITs) are one of the most popular income-oriented types of stocks investors can purchase. Receiving monthly or quarterly dividend payments on a regular basis is... 
Via Benzinga
Why Shares of Legend Biotech Jumped Wednesday
A leaked abstract on a phase 3 trial for the company's multiple myeloma drug Carvykti gave the stock a jolt. 
Via The Motley Fool
Legend Biotech Breaks Out After Leaked Documents Show Big CAR-T Benefit
The company could have the best-in-class CAR-T drug for multiple myeloma patients. 
Via Investor's Business Daily
Evaxion Biotech Says Personalized Cancer Immunotherapy Meets Primary Endpoint In Melanoma Patients
Via Benzinga
Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
7 Sorry Pharma Stocks to Sell in April Before It’s Too Late
You have to be patient when investing in pharma stocks. But sometimes the risk and the wait aren't worth the rewards. 
Via InvestorPlace
Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials
This month, H.C. Wainwright & Co. 
Via Benzinga
Hillstream BioPharma's Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To Grow
A surge in oncology drug development, coupled with increased patient access and early diagnosis, has resulted in a massive increase in global spending on cancer treatments. Due to this, the global... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Large Cap Biopharmaceuticals Q1 2023: In This Bullish Run Biotech Lags
It was very difficult to make money in Q1 trading healthcare or biotech ETFs because of the sharp rally in other sectors. Nonetheless, there were two big winners. 
Via Talk Markets
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
67 68 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.